CDK4 and gastric cancer: Professor Shen has conducted a preliminary exploration of the role of CDK4/6 inhibitors in GC, finding that the disease control rate of CDK4/6 inhibitors in combination with Pyrotinib in GC is as high as 93.8% [13].